Policy Insights papers

  1. Impact of Electronic Health Record Interface Design on Unsafe Prescribing of Ciclosporin, Tacrolimus, and Diltiazem: Cohort Study in English National Health Service Primary Care

    JMIR EHR design paper

    Categories

    • OpenPrescribing
    • Policy Insights

  2. The NHS deserves better use of hospital medicines data

    Hospitals Data BMJ Paper

    Categories

    • OpenPrescribing
    • Policy Insights

  3. Bringing NHS data analysis into the 21st century

    JRSM Paper on NHS Analytics

    Categories

    • Open Working
    • Policy Insights

  4. Better use of data and digital offer rapid opportunities to address covid-19

    COVID-19 digital and data BMJ Blog

    Categories

    • Open Working
    • OpenPathology
    • OpenSAFELY
    • Policy Insights

  5. The poor performance of apps assessing skin cancer risk

    BMJ Skin apps paper

    Categories

    • Policy Insights

  6. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study

    Lancet FDAAA Paper

    Categories

    • Policy Insights
    • TrialsTracker

  7. Barriers to Working With National Health Service England's Open Data

    JMIR Barriers paper

    Categories

    • Open Working
    • Policy Insights

  8. Why researchers should share their analytic code

    BMJ Editorial

    Categories

    • Open Working
    • Policy Insights
    • Research Integrity

  9. FDAAA TrialsTracker: A live informatics tool to monitor compliance with FDA requirements to report clinical trial results

    FDAAA TrialsTracker Pre-Print

    Status
    Preprint

    Categories

    • Policy Insights
    • TrialsTracker

  10. Why did some practices not implement new antibiotic prescribing guidelines on urinary tract infection? A cohort study and survey in NHS England primary care

    Describing trends and geographical variation in prescribing of trimethoprim and nitrofurantoin to treat urinary tract infections

    Categories

    • OpenPrescribing
    • Policy Insights

  11. Too few trials or too few reported trials?

    Highlighting that there is a serious ongoing issue with the results of completed trials not being reported.

    Categories

    • Policy Insights
    • TrialsTracker

  12. Why Cochrane should prioritise sharing data

    Discussing Cochrane's practice on data sharing.

    Categories

    • Open Working
    • Policy Insights
    • Research Integrity

  13. Noncommercial Funders' Policies on Trial Registration, Access to Summary Results, and Individual Patient Data Availability.

    Assessing trials transparency policies from a sample of noncommercial funders

    Categories

    • Policy Insights
    • Research Integrity

  14. Impact of NICE guidance on tamoxifen prescribing in England 2011–2017: an interrupted time series analysis

    Measuring the uptake of tamoxifen, and the alternative raloxifene, in national prescribing data sets

    Categories

    • OpenPrescribing
    • Policy Insights

  15. A cross-sectional study of all clinicians' conflict of interest disclosures to NHS hospital employers in England 2015-2016.

    Documenting how NHS trusts in the UK record and share disclosures of conflict of interest by their employees

    Categories

    • Policy Insights
    • Research Integrity

  16. Make journals report clinical trials properly

    Describing the need for better reporting of clinical trials.

    Categories

    • Policy Insights
    • TrialsTracker

  17. Fixing flaws in science must be professionalized

    Discussing the need for greater transparency around data and analytics.

    Categories

    • Policy Insights
    • Research Integrity

  18. Antivirals, pandemic planning, and failure to heed calls for trial data

    Editorial

    Categories

    • Policy Insights
    • TrialsTracker

  19. How medicine is broken, and how we can fix it

    Editorial

    Categories

    • Policy Insights
    • Research Integrity

  20. How to get all trials reported: audit, better data, and individual accountability

    Discussing the rationale for WHO's new position calling for prompt reporting and public disclosure of interventional clinical trial results

    Categories

    • Policy Insights
    • TrialsTracker